Assay

Enterome to present world first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics™ therapeutic cancer vaccine, at ASCO 2022

Retrieved on: 
Thursday, May 19, 2022
CD8, Immunotherapy, Company, CD22, Cancer, Annual general meeting, CD37, Oncology, BIRC5, Mimicry, Rituximab, Degenerative disease, 2021 Essex County Council election, Patient, Lenalidomide, CD4, Assay, CD20, Cytokine, Society, American Society of Clinical Oncology, IL13RA2, CD268, Peptide, Antigen, Molecular mimicry, Glioblastoma, ASCO, Colorectal cancer, Therapy, Hormone, FOXM1, Nivolumab, Immune system, Protein, ESMO, CEO, Vaccine, Pharmaceutical industry

PARIS, May 19, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces that it will present for the first time proof-of-concept data from clinical trials with EO2401, its first-in-class off-the-shelf OncoMimics™ cancer immunotherapy at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually. 

Key Points: 
  • To-date, Enterome has generated a repertoire of OncoMimics peptides correlating to tumor antigens across a wide range of solid and liquid tumor types.
  • From this, the Company is creating a pipeline of off-the-shelf cancer immunotherapies designed to act via the same novel mode of action.
  • EO2463 combines four OncoMimics peptides that exhibit molecular mimicry with the B cell markers CD20, CD22, CD37, and CD268 (BAFF-receptor), respectively.
  • "We are thrilled to be able to present the first clinical data demonstrating the potential of our unique OncoMimics pipeline at ASCO this year.

Measuring endocrine disruptors in wastewater

Retrieved on: 
Tuesday, April 12, 2022
Method, Cell, Risk, Hormone, Literature, Varennes-en-Argonne, Endocrine disruptor, Institute, Research, Doctor of Philosophy, INRS, Environment, Interdisciplinarity, Bouquet (EP), MONTRAL, Assay, Student, Biophysical environment, Sewage

QUBEC and MONTRAL, April 12, 2022 /CNW Telbec/ - Treating pollutants, such as endocrine disruptors, is an effective way to protect the environment.

Key Points: 
  • QUBEC and MONTRAL, April 12, 2022 /CNW Telbec/ - Treating pollutants, such as endocrine disruptors, is an effective way to protect the environment.
  • Endocrine disruptors are chemicals that alter the hormonal systems and the development of organisms that are exposed to them, even in small quantities.
  • "There is interest in Qubec and around the world in finding ways to track endocrine disruptors.
  • The challenge in monitoring wastewater comes from the "cocktail" of endocrine disruptors it contains.

Clayton Pharmaceuticals and VistaPharm (a Vertice company) Receive FDA Approval for Sucralfate Oral Suspension

Retrieved on: 
Thursday, April 7, 2022
Partnership, CGT, Research, CEO, Assay, Biology, FDA, Patient, ANDA, Generic drug, Pharmaceutical industry, IQVIA, Vertical integration

EXTON, Pa. , April 7, 2022 /PRNewswire/ -- Clayton Pharmaceuticals, a thought leader and pioneer in developing innovative pathways to establish bioequivalence for complex generic drug products, announces that they have received FDA approval for Sucralfate Oral Suspension with Competitive Generic Therapy (CGT) designation.

Key Points: 
  • EXTON, Pa., April 7, 2022 /PRNewswire/ -- Clayton Pharmaceuticals, a thought leader and pioneer in developing innovative pathways to establish bioequivalence for complex generic drug products, announces that they have received FDA approval for Sucralfate Oral Suspension with Competitive Generic Therapy (CGT) designation.
  • Dr. Sid Bhoopathy, the President and CEO of Clayton Pharmaceuticals, commented "This ANDA approval using welldesigned, scientifically sound in vitro bioassays endorses the use of novel approaches to demonstrate product bioequivalence.
  • Scott Meyers, CEO of Vertice, shared "I am proud that the strong collaboration between our companies has resulted in an FDA approval for Sucralfate Oral Suspension.
  • Congratulations also for the outstanding operational execution that resulted in us quickly receiving CGT designation for this product following FDA approval."

Core One Labs’ Akome Receives Positive Results from Bioassay Studies

Retrieved on: 
Saturday, April 2, 2022
Company, Lists of diseases, Akome, Patent, Corona Labs Inc., AD, WKN, Stroke, Research, Biotechnology, PD, Neurological disorder, USPTO, Technology, Industry, Inflammation, Database, GLOBE, Psilocybin, Drug discovery, News, Assay, OTC, Patient, CSE, Depression, Pharmaceutical industry

Neuro-Zones bioassay studies have allowed researchers to assess the effect of Akomes plant bioactives on various biological targets associated with the neurological indications in question.

Key Points: 
  • Neuro-Zones bioassay studies have allowed researchers to assess the effect of Akomes plant bioactives on various biological targets associated with the neurological indications in question.
  • Positive results emerging from the bioassay studies indicate that Akomes plant bioactives possess the desired biological effects against Alzheimers Disease neuropathological mechanisms, as well as against other neuroinflammatory processes.
  • Using these positive results Akome and Neuro-Zone are actively mapping out the next stages in the Companys drug development process.
  • The positive results from these studies have demonstrated that Akome is making significant steps towards developing groundbreaking drug formulations that can be used to treat neurological diseases.

Cyclica and Arctoris to Expand Partnership to Advance Drug Discovery Programs for Alzheimer's Disease

Retrieved on: 
Wednesday, March 23, 2022
Oncology, Mental Health, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Disease, Polypharmacology, Neurodegeneration, Inc., Machine learning, Neurology, Automation, Multimedia, Research, CEO, Entrepreneurship, MD, Alzheimer's disease, Drug discovery, Assay, Patient, Partnership, Pharmaceutical industry, Fine chemical, CYCLICA, ARCTORIS

Cyclica Inc. (Cyclica), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, and Arctoris Ltd. (Arctoris), a tech-enabled biopharma company that combines its unique automation with computational approaches to progress drug discovery, have agreed to expand their partnership to progress drug discovery programs for novel neurodegenerative targets with a focus on Alzheimers disease.

Key Points: 
  • Cyclica Inc. (Cyclica), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, and Arctoris Ltd. (Arctoris), a tech-enabled biopharma company that combines its unique automation with computational approaches to progress drug discovery, have agreed to expand their partnership to progress drug discovery programs for novel neurodegenerative targets with a focus on Alzheimers disease.
  • Dr. Martin-Immanuel Bittner, MD DPhil FRSA, CEO of Arctoris, comments by sharing, Our joint drug discovery program focuses on dual specificity inhibitors - a very promising yet also challenging modality.
  • Cyclica and Arctoris have long-term plans for their partnership as discussions are already underway about tackling additional therapeutic targets.
  • This press release contains forward-looking statements and forward-looking information which include, among other things, plans to advance drug discovery programs by Cyclica and Arctoris.

Companion Diagnostics Market Geographic Growth Opportunities: Asia-Pacific to Register Highest Growth Rate in Companion Diagnostics Market During 2022-2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 22, 2022
Biotechnology, Pharmaceutical, Health, PCR, Assay, Colorectal cancer, Software, IHC, Drug development, Product-service system, Adoption, Biomarker, USD, ISH, NGS, Cancer, Personal Software Services, CAGR, Lung, Blood, Research, Incidence, Cros, Medical device, Healthcare, Breast, Technology

The global companion diagnostics market is projected to reach USD 9.9 billion by 2026 from USD 5.5 billion in 2021, at a CAGR of 12.6% during the forecast period.

Key Points: 
  • The global companion diagnostics market is projected to reach USD 9.9 billion by 2026 from USD 5.5 billion in 2021, at a CAGR of 12.6% during the forecast period.
  • Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and the growing adoption of targeted therapies.
  • Based on product & service, the companion diagnostics market is segmented into assays, kits & reagents, and software & services.
  • Based on end-user, the companion diagnostics market is segmented into pharmaceutical & biotechnology companies, reference laboratories, CROs, and other end users.

Point of Care Molecular Diagnostics Market by Product, Application, Technology, End-user and Region - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 16, 2022
Science, Health, Other Science, Other Health, Product-service system, Degenerative disease, HIV, Subclinical infection, Assay, Prevalence, STD, HPV, Infection, Awareness, Intensive care unit, Trichomonas vaginalis, Vertically transmitted infection, Instrument, USD, Eyeish, Software, Physician, Growth, POC, CAGR, Medical imaging, Vaccine, Medical device, Technology, Hepatitis, Cancer, Hospital, Trichomonas

The global point-of-care molecular diagnostics market size is projected to reach USD 4.1 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 8.2% during the forecast period.

Key Points: 
  • The global point-of-care molecular diagnostics market size is projected to reach USD 4.1 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 8.2% during the forecast period.
  • The assays & kits accounted for the highest growth rate in the point-of-care molecular diagnostics market, by product & service, during the forecast period
    The point-of-care molecular diagnostics market is segmented into assays & kits, instruments & analyzers and software and services.
  • The assays & kits segment accounted for the highest growth rate in the point-of-care molecular diagnostics market in 2020.
  • The global point-of-care molecular diagnostics market is segmented into North America, Europe, Asia Pacific and the Rest of the World.

Applied DNA Submits Request for Emergency Use Authorization to FDA for Linea™ 2.0 COVID-19 Assay and Linea™ Unsupervised At-Home Sample Collection Kit

Retrieved on: 
Friday, January 21, 2022
FDA, Health, Infectious Diseases, Genetics, Pharmaceutical, Biotechnology, CDC, Securities Exchange Act of 1934, CMS, Vaccination, PCR, Research, Assay, Forward-looking statement, Applied DNA Sciences, LinkedIn, New York State Department of Health, RT, Private Securities Litigation Reform Act, SEC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Textile, RNA, COVID-19, Severe acute respiratory syndrome coronavirus 2, NYSDOH, NASDAQ, Cannabis, EUA, CEO, DNA, COVID-19 testing, Health, History, Collection, CRISPR, Company, Immunity, Russell, Workforce, Cancer, Food, Contract, Twitter, FDA, TCR, Infection, Polymerase chain reaction, LLC, Drug Quality and Security Act, Omicron, Securities Act of 1933, Annual report, Acquisition, Vaccine, Applied Food Technologies

The Linea 2.0 Assay is a high-throughput multiplex RT-PCR assay targeting the E and N genes of SARS-CoV-2.

Key Points: 
  • The Linea 2.0 Assay is a high-throughput multiplex RT-PCR assay targeting the E and N genes of SARS-CoV-2.
  • The Assay is variant agnostic, can detect all known SARS-CoV-2 variants, and is validated for single sample and robotic pooled testing.
  • The Assay previously received conditional approval from the New York State Department of Health in late December 2021.
  • The Linea Collection Kit is designed to enable the simple self-collection of nasal swab specimens without supervision by medical personnel.

Clinical Evaluation of LeSoleil Against COVID-19

Retrieved on: 
Thursday, January 6, 2022
Nuclear, Respiration, CCL8, Respiratory tract, Severe acute respiratory syndrome coronavirus 2, COVID-19, Drug discovery, Omicron, Assay, Heme, Acquisition, Oxidative stress, H5N1, Research, Patient, Biomedical Research, IL-6, PCT, Delta, HO-1, Peroxisome, Drug design, Health, Infection, Creatinine, Inflammation, Economic development, International Drug Policy Consortium, Incidence, Interleukin 1 beta, Lymphocyte, Protocol, R, Death, Warfarin necrosis, Nrf2 internal ribosome entry site (IRES), Pharmaceutical industry, Vaccine, H7N9, SunTrap, H1N1

The Suntrap team believes that the prevention and treatment of COVID-19 should focus on the development of multi-targeted and broad-spectrum anti-coronavirus drugs.

Key Points: 
  • The Suntrap team believes that the prevention and treatment of COVID-19 should focus on the development of multi-targeted and broad-spectrum anti-coronavirus drugs.
  • Based on the clinical symptoms and pathogenic mechanism of patients infected with SARS-CoV-2, the Suntrap research team optimized and developed different clinical protocols.
  • LeSoleil broad-spectrum anti-coronavirus protective and therapeutic spray can cope with the prevention and treatment of SARS-CoV-2 and variant strains (e.g., Delta and Omicron.).
  • To further in-depth clinical research of LeSoleil anti-SARS-CoV-2 drugs, and deter COVID-19 as an obstacle for social stability, economic development and human health, Suntrap recruits qualified clinical research institutions around the world to carry out clinical evaluation studies on the efficacy of the LeSoleil broad-spectrum anti-coronavirus drug series against mutant strains of SARS-CoV-2.

Menarini Silicon Biosystems Announces Study Results Presented at American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Tuesday, December 14, 2021
CMMC, Disease management, Nxt, International Myeloma Foundation, Doctor of Philosophy, CNV, Assay, Disease, MSB, Solution, Multiple Myeloma Research Foundation, FDA, Research, ISO, Genomics, Education, NCI-designated Cancer Center, Adult, Hospital, Biomarker, Immunotherapy, MM, Blood, Inflore, MMRF, ASH, Society, Quantification, SMM, Dana–Farber Cancer Institute, Cancer, Bone marrow, CEO, Biotechnology, Tissue, Liquid biopsy, MGUS, Precision medicine, Silicon, Industry, Harvard Medical School, News, Patient, Medical imaging, Fine chemical, Pharmaceutical industry, Medicine, Multiple myeloma

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Dec. 14, 2021 /PRNewswire/ -- Menarini Silicon Biosystems (MSB), a pioneer of liquid biopsy and single cell technologies today announced that Dana-Farber Cancer Institute and the Multiple Myeloma Research Foundation presented data in an oral presentation at the 2021 ASH Annual Meeting that showcases the importance of Non-Invasive Liquid Biopsy to Quantify and Molecularly Characterize Circulating Multiple Myeloma Cells (CMMC).

Key Points: 
  • Menarini Silicon Biosystems Announces Study Results Presented at American Society of Hematology (ASH) Annual Meeting Highlighting CELLSEARCHCMMC assay, a Non-Invasive Liquid Biopsy for the Quantification and Molecular Characterization of Circulating Multiple Myeloma Cells
    The study analysed185blood samples fromprecursor patients (75MGUS and110SMM) from the Dana-Farber Cancer Institute observational PCROWD study.
  • The oral presentation took place at the ASH 2021 Annual Meeting in Atlanta on Saturday December 11th at 10:45am.
  • "As a patient focused organization, the MMRF is committed to advancing innovative research to improve clinical care and disease management.
  • The Menarini Silicon Biosystems (MSB) Lab Services represent a global, comprehensive and integrated laboratory service involving state-of-the-art technologies.